<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342377</url>
  </required_header>
  <id_info>
    <org_study_id>clns_10696</org_study_id>
    <nct_id>NCT04342377</nct_id>
  </id_info>
  <brief_title>The Canada Lymph Node Score Project: A Crossover Trial</brief_title>
  <acronym>CLNS</acronym>
  <official_title>Improving Preoperative Lung Cancer Staging Through the Canada Lymph Node Project: A Pan-Canadian Multicentered Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Sciences Centre, Winnipeg, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Alexandra Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Before deciding on treatment for patients with lung cancer, a critical step in the
      investigation is finding out whether the lymph nodes in the chest contain cancer cells. This
      is accomplished with a biopsy of the lymph nodes through the airway wall, known as
      Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. Guidelines require that
      every single lymph node in the chest be biopsied through a process called Systematic
      Sampling. However, emerging data suggests that the lymph nodes that appear benign on imaging
      and ultrasound do not need a biopsy. A proposed alternative to the inefficient Systematic
      Sampling is the simplified Selective Targeted Sampling of the lymph nodes, whereby only lymph
      nodes that look malignant are biopsied. This trial will evaluate the simplified Selective
      Targeted Sampling of lymph nodes and compare it to Systematic Sampling to see whether it is
      equally as effective in staging lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment decisions in Non-Small Lung Cancer (NSCLC) are reliant on a thorough staging
      process that includes imaging with Computed Tomography (CT), Positron Emission Tomography
      (PET) and Systematic Sampling (SS) of mediastinal lymph nodes (LNs) by Endobronchial
      Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA). Collectively, the results of these
      staging procedures dictate whether patients will be treated with surgery, radiation and/or
      chemotherapy. Current guidelines for SS through EBUS-TBNA mandate the biopsy of at least 3
      mediastinal LN stations (4R, 4L and 7) in the chest, even if they appear normal on CT and PET
      scan. Despite improvements in diagnostic techniques and safety, LN biopsies remain onerous
      for the patient and costly to our healthcare system. SS is also unreliable, yielding
      inconclusive pathology results in 42.14% of cases, especially for Triple Normal LNs, which
      are LNs that appear normal on PET, and CT, and EBUS. In fact, SS results in mostly negative
      or inconclusive biopsies for Triple Normal LNs, which may be due in part to their very low
      probability (&lt; 6%) of malignancy. As such, the researchers have proposed to replace the
      onerous and unreliable process of SS by a simpler Selective Targeted Sampling (STS) staging
      process. In STS, Triple Normal LNs will not be biopsied, due to the very high negative
      predictive value (NPV) of malignancy. STS follows the simple notion that only LNs that have
      the potential to be malignant should be biopsied, whereas LNs which are very likely benign
      (i.e. Triple Normal LNs) should not be biopsied.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A prospective pan-Canadian, multicentered, non-inferiority crossover study design</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-Inferiority Margin between Selective Targeted Sampling and Systematic Sampling</measure>
    <time_frame>2 years</time_frame>
    <description>A margin of 5% or less would be considered satisfactory for STS to be deemed non-inferior to SS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Statistics (between staging methods)</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitivity, specificity, negative predictive value and positive predictive value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agreement (between staging methods)</measure>
    <time_frame>2 years</time_frame>
    <description>Based on Cohen's Kappa statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inconclusive Biopsy Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of lymph nodes with inconclusive pathology from biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Yield (accuracy)</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of lymph nodes with a pathological diagnosis for both sampling methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Procedure Length</measure>
    <time_frame>2 years</time_frame>
    <description>For each sampling method (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Cost per Procedure</measure>
    <time_frame>2 years</time_frame>
    <description>For each sampling method (sum of dollar costs for EBUS procedure)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer Stage I</condition>
  <condition>Non-small Cell Lung Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>Selective Targeted Sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:
Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter &lt; 1 cm), AND normal on PET (SUV &lt; 2.5), AND normal on EBUS (CLNS &lt; 2). Lymph nodes that are found to be Triple Normal will be marked as &quot;Not for Biopsy&quot;, whereas all other lymph nodes will be biopsied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systematic Sampling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:
Systematic Sampling - all lymph nodes previously marked as &quot;Not for Biopsy&quot; will be biopsied.
At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Selective Targeted Sampling</intervention_name>
    <description>Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.</description>
    <arm_group_label>Selective Targeted Sampling</arm_group_label>
    <other_name>STS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Systematic Sampling</intervention_name>
    <description>All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.</description>
    <arm_group_label>Systematic Sampling</arm_group_label>
    <other_name>SS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Both CT and PET scans completed prior to EBUS

          -  Suspected or confirmed NSCLC requiring mediastinal staging

          -  cN0-cN1 as indicated by CT and PET scans

        Exclusion Criteria:

          -  Patients with cN0 disease AND peripheral tumors AND tumor &lt; 2 cm in diameter, as they
             do not require mediastinal staging

          -  Evidence of cN2 disease or higher on CT and PET scans
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
    <phone>(905) 522-1155</phone>
    <phone_ext>35916</phone_ext>
    <email>hannaw@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yogita Patel, BSc</last_name>
    <phone>(905) 522-1155</phone>
    <phone_ext>35096</phone_ext>
    <email>patelys@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon R Turner, MD, MEd, FRCSC</last_name>
      <phone>(780) 492-6621</phone>
      <email>sturner@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Simon R Turner, MD, MEd, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Biniam Kidane, MD, MSc, FRCSC</last_name>
      <phone>(204) 787-3109</phone>
      <email>bkidane@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Biniam Kidane, MD, MSc, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
      <phone>(905) 522-1155</phone>
      <phone_ext>35916</phone_ext>
      <email>hannaw@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
      <phone>(905) 522-1155</phone>
      <phone_ext>35916</phone_ext>
      <email>hannaw@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Waël C Hanna, MDCM, MBA, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kazuhiro Yasufuku, MD, PhD, FCCP</last_name>
      <phone>(416) 340-4729</phone>
      <email>kazuhiro.yasufuku@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Kazuhiro Yasufuku, MD, PhD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Endoscopic Tracheo-bronchial and Oesophageal Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Moishe Liberman, MD, PhD, FACS, FRCSC</last_name>
      <phone>(514) 890-8000</phone>
      <phone_ext>26832</phone_ext>
      <email>moishe.liberman@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Moishe Liberman, MD, PhD, FACS, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC Interventional Pulmonology Department</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3S9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Gonzalez, MD, MSc</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>32117</phone_ext>
      <email>anne.gonzalez@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Anne Gonzalez, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Wael Hanna</investigator_full_name>
    <investigator_title>Lead Investigator</investigator_title>
  </responsible_party>
  <keyword>Mediastinal Staging</keyword>
  <keyword>Nodal Disease</keyword>
  <keyword>Endobronchial Ultrasound</keyword>
  <keyword>Diagnostic Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

